StreetInsider.com News Articles

Form 6-K BIOHARVEST SCIENCES INC. For: May 27

Thu, 28 May 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260528/26563198.html

Form 6-K BIOHARVEST SCIENCES INC. For: May 27

Thu, 28 May 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260528/26563198.html

Tate & Lyle expands sweetener collaboration with BioHarvest Sciences

Mon, 18 May 2026 07:06:33 -0400

Tate & Lyle PLC has expanded its collaboration with BioHarvest Sciences Inc. (NASDAQ: BHST) to develop multiple plant-based sweetener molecules, broadening their joint sweetener development program that began in 2024.

The expanded partnership aims to create sweetening solutions tailored to different food and beverage categories. The collaboration utilizes BioHarvest's Botanical Synthesis platform, which produces plant-based, non-GMO ingredients without traditional agricultural extraction methods.

Victoria Spadaro-Grant, Chief Science and Innovation Officer at Tate & Lyle, said the expansion reflects technical progress achieved and aims to expand their sweetening solutions toolkit. She noted that multiple unmet market needs are unlikely to be addressed with a

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

Mon, 18 May 2026 07:00:00 -0400

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.

The expanded collaboration builds on the initial agreement signed

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

Mon, 18 May 2026 07:00:00 -0400

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

The expanded collaboration builds on the initial agreement signed

Form 6-K BIOHARVEST SCIENCES INC. For: May 14

Thu, 14 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26494265.html

Form 6-K BIOHARVEST SCIENCES INC. For: May 14

Thu, 14 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26494265.html

Form 6-K BIOHARVEST SCIENCES INC. For: Mar 31

Thu, 14 May 2026 13:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26493065.html

Form 6-K BIOHARVEST SCIENCES INC. For: Mar 31

Thu, 14 May 2026 13:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26493065.html

Form 6-K BIOHARVEST SCIENCES INC. For: May 12

Thu, 14 May 2026 10:27:00 -0400

si-local-file:///var/storage/secattach/20260514/26491855.html

Form 6-K BIOHARVEST SCIENCES INC. For: May 12

Thu, 14 May 2026 10:27:00 -0400

si-local-file:///var/storage/secattach/20260514/26491855.html

BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 07:00:00 -0400

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million

CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY

VINIA brand customer base grows to 90,000 active users as of the end of April

Two-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today

BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 07:00:00 -0400

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million

CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY

VINIA brand customer base grows to 90,000 active users as of the end of April

Two-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses

BioHarvest Sciences names Nedira Salzman-Frenkel business development VP

Wed, 13 May 2026 17:38:58 -0400

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) appointed Nedira Salzman-Frenkel as Vice President of Business Development for its contract development and manufacturing organization division, according to a company statement.

Salzman-Frenkel will focus on securing contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic sectors for the company's CDMO business. The appointment aligns with BioHarvest's strategy to establish partnerships with customers ahead of launching a new facility next year.

"Nedira brings over a decade of experience in the life sciences industry, including securing contracts with pharmaceutical companies and other related sectors," said Dr. Zaki Rakib in the statement.

Salzman-Frenkel previously served as Vice President of Business

BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

Wed, 13 May 2026 17:32:00 -0400

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and manufacturing organization (CDMO) business.

- CDMO program advances to Stage 2 of development agreement valued at $1.125 million

-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals

- In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition

Vancouver, British Columbia and Rehovot, Israel---(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has completed Stage 1 under a multi-stage development

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications

Wed, 13 May 2026 08:00:00 -0400

- CDMO program advances to Stage 2 of development agreement valued at $1.125 million

-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals

- In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition

Form 6-K BIOHARVEST SCIENCES INC. For: May 12

Tue, 12 May 2026 14:28:00 -0400

si-local-file:///var/storage/secattach/20260512/26476860.html

Form 6-K BIOHARVEST SCIENCES INC. For: May 12

Tue, 12 May 2026 14:28:00 -0400

si-local-file:///var/storage/secattach/20260512/26476860.html

Form 6-K BIOHARVEST SCIENCES INC. For: May 12

Tue, 12 May 2026 14:28:00 -0400

si-local-file:///var/storage/secattach/20260512/26476860.html

BioHarvest Sciences secures $1.2M contract for rare fragrance development

Tue, 12 May 2026 07:32:54 -0400

BioHarvest Sciences Inc. (NASDAQ: BHST) announced it signed a $1.2 million Stage 2 contract for developing a rare fragrance compound through its botanical synthesis platform. The contract follows the completion of Stage 1 in March 2026, during which the company produced a stable cell bank containing rare molecules.

The fragrance compound is derived from a plant considered one of the most valuable fragrance raw materials globally, with premium grades priced at tens of thousands of dollars per kilogram. The Stage 2 development phase is expected to take six to nine months and will produce sufficient material for commercial trials.

Under the agreement,